Latest Breaking News On - China national biotec group co ltd - Page 2 : comparemela.com

KUALA LUMPUR: CGS-CIMB Equities Research is retaining its Add call for Duopharma Biotech with an unchanged target price of RM3.67 due to the potential long-term earnings prospects from the development of vaccine manufacturing capabilities, which is a key rerating catalyst. It said on Monday it was keeping its forecasts intact for now pending the details or further developments in the supply agreement for the Sinopharm vaccine, which it thinks could be signed by end of the month. “We retain our Add call on the stock with an unchanged TP of RM3.67 based on a CY22F P/E of 28.8 times (+2 standard deviations from its five-year mean),” the research house said.

Kuala lumpurKhairy jamaluddinEquities researchGamaleya institute of russiaMalaysia drug control authorityChina national biotec group co ltdImmunisation programmeWorld health organisationNational covidDrug control authorityVero cellCoordinating ministerGlobal accessGamaleya instituteகுவாலா லம்பூர்கைரி ஜமாலுதீன்